Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).

The analyst commented, "On 8/13, Lucid Diagnostics (LUCD, OW) reported 2Q25 operating results and provided corporate updates. Specifically, LUCD reported 2Q25 revenue of $1.2 million (Cantor $1.5 million / FactSet consensus $1.1 million), representing YoY growth of ~19% driven by increased EsoGuard volume. The company performed 2,756 tests in the quarter, within the company's target range of 2500-3000 tests per quarter. Looking ahead, MolDx will convene a Contractor Advisory Committee (CAC) on September 4, 2025 to evaluate clinical evidence related to EsoGuard as part of the reconsideration process for LCD L39256. This marks a key milestone towards securing Medicare coverage, and the company believes the participating medical experts will offer strong support for EsoGuard's clinical utility in nonendoscopic esophageal precancer testing. Importantly, LUCD believes the company is very close to receiving a local coverage decision to secure Medicare Coverage for EsoGuard, which would change the story from one of volume growth to revenue."

For an analyst ratings summary and ratings history on Lucid Diagnostics Inc click here. For more ratings news on Lucid Diagnostics Inc click here.

Shares of Lucid Diagnostics Inc closed at $1.02 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027